▶ PINEALON · SUBTOPIC · MECHANISM
PINEALON Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Synthetic tripeptide Glu-Asp-Arg developed at the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson group) as a short-peptide bioregulator targeting brain tissue. Hypothesized mechanism: tissue-specific gene-expression modulation via DNA binding. Russian preclinical data on neuroprotection and oxidative-stress reduction.
PHARMACOKINETIC HALF-LIFE
Reported half-life for PINEALON: Short (minutes) plasma · longer CNS retention reported. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
PINEALON is a defined sequence: Glu-Asp-Arg. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
PINEALON is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
Bioregulator tetrapeptides are short synthetic peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson's group. The class is built on the hypothesis that short peptide bioregulators bind specific DNA sequences and modulate tissue-specific gene expression. Epitalon (Ala-Glu-Asp-Gly) is the pineal-derived bioregulator; Pinealon (Glu-Asp-Arg) is a tripeptide bioregulator targeting brain tissue. Russian clinical literature describes decades of use; mainstream Western RCT-grade evidence is limited.
Nootropic compounds act on canonical CNS pathways · BDNF / TrkB neurotrophic signaling, monoamine modulation, and GABAergic regulation. Russian-developed heptapeptides Semax and Selank are the most-studied research nootropics in the Peppu Studio catalog, both built on the same C-terminal Pro-Gly-Pro stabilizing strategy.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Khavinson group preclinical evidence describes reduced oxidative damage and improved neuronal survival in stress models.
Khavinson hypothesis: short peptides bind specific DNA promoter sequences to modulate tissue-specific gene expression. Limited replication outside Russian Academy of Sciences.
Limited Western-indexed RCT evidence as of 2026.
MECHANISM Q+A
▶ How does Pinealon work?
The Khavinson hypothesis proposes that short peptide bioregulators bind specific DNA promoter sequences and modulate tissue-specific gene expression. Pinealon is hypothesized to bind brain-tissue-specific promoters. The mechanism remains debated outside the Russian Academy of Sciences with limited Western replication.
▶ What's the half-life of Pinealon?
Short plasma half-life (minutes). CNS retention is reportedly longer. Russian clinical protocols use intranasal administration to enhance brain delivery.
CITED LITERATURE
- Khavinson VK, Kuznik BI, Tarnovskaya SI. Short peptides and gene regulation in aging. Bull Exp Biol Med 2012. link
- Khavinson VK et al.. Neuroprotective effects of Khavinson's short peptides in stress models. Bull Exp Biol Med 2014. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25